Fisher Asset Management LLC Reduces Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Fisher Asset Management LLC trimmed its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 1.3% during the third quarter, HoldingsChannel reports. The institutional investor owned 1,371,562 shares of the biopharmaceutical company’s stock after selling 17,452 shares during the period. Fisher Asset Management LLC’s holdings in Dynavax Technologies were worth $15,279,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Millennium Management LLC purchased a new position in Dynavax Technologies during the 2nd quarter worth $17,615,000. Great Point Partners LLC grew its position in Dynavax Technologies by 87.7% during the 2nd quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock worth $26,660,000 after purchasing an additional 1,109,080 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in Dynavax Technologies during the 3rd quarter worth $8,291,000. Mizuho Markets Americas LLC grew its position in Dynavax Technologies by 37.9% during the 2nd quarter. Mizuho Markets Americas LLC now owns 1,175,107 shares of the biopharmaceutical company’s stock worth $13,196,000 after purchasing an additional 323,050 shares during the last quarter. Finally, Swedbank AB purchased a new position in Dynavax Technologies during the 1st quarter worth $3,740,000. 96.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

DVAX has been the topic of several research reports. HC Wainwright reissued a “buy” rating and set a $29.00 price objective on shares of Dynavax Technologies in a research report on Friday, November 8th. The Goldman Sachs Group lowered their price objective on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th.

Dynavax Technologies Stock Up 2.0 %

DVAX stock opened at $12.91 on Thursday. Dynavax Technologies Co. has a one year low of $9.74 and a one year high of $15.01. The stock has a market capitalization of $1.70 billion, a PE ratio of 99.32 and a beta of 1.34. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The company has a fifty day moving average of $11.59 and a 200-day moving average of $11.36.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.